Jwa Hoon Kim

Abstract This open-label, single-arm, multi-center phase II study investigated the clinical activity and safety of alpelisib in combination with capecitabine in patients with PIK3CA-mutant metastatic colorectal cancer who had progressed after standard chemotherapy. Patients received oral alpelisib and capecitabine in 21-day cycles, and clinical outcomes and circulating tumor DNA were longitudinally assessed. A total of 26 patients were enrolled across nine institutions.

ORIGINAL RESEARCH Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience Yoon‐Koo Kang Corresponding Author E-mail address: ykkang@amc.seoul.kr Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Correspondence Yoon‐Koo Kang, Department of Oncology, Asan Medical Center, University of Ulsan College of...